Lunai Bioworks amends 8-K to disclose Nasdaq MVLS noncompliance delisting basis

• Lunai Bioworks filed an amended Form 8-K to update its earlier report with an additional Nasdaq staff determination letter received April 28, 2026.
• Letter warned continued failure to meet Nasdaq Listing Rule 5550(b)(2) market value of listed securities threshold of $35 million, with grace period expiring April 27, 2026, could serve as an additional basis for delisting.
• Nasdaq Hearings Panel previously granted an exception through May 1, 2026 to regain compliance via stockholders’ equity alternative, with bid-price compliance deadline set for June 1, 2026.
• Merger completed May 1, 2026 included issuance of Series B Preferred Stock with aggregate stated value of $20 million, aimed at supporting equity compliance.
• Stockholders authorized a reverse stock split range of 1-for-3 to 1-for-30 on May 8, 2026, with company seeking a short extension to meet bid-price rule following a meeting delay.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001731122-26-000705), on May 11, 2026, and is solely responsible for the information contained therein.